Funding for this research was provided by:
Multiple Sclerosis Society of Canada (Operating Grant (2017-2020))
Text and Data Mining valid from 2019-06-25
Received: 15 April 2019
Accepted: 16 June 2019
First Online: 25 June 2019
Ethics approval and consent to participate
: This trial has already received research ethics approval from the Queen’s University Health Sciences & Affiliated Teaching Hospitals Research Ethics Board (HSREB), the University of Alberta Health Research Ethics Board- Health Panel, and the University of Calgary Conjoint Health Research Ethics Board (CHREB). Written informed consent to participate will be obtained by the research assistants prior to baseline data collection for individuals screened and deemed eligible for the study.
: KT is a PhD student at the University of Alberta and is also a medical science liaison for LEO Pharma Canada. PS is a consultant for Novartis Pharmaceuticals for an educational project. She has received honoraria from the MS Society of Canada when speaking to the public. MF and NA declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.